Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Suvretta Capital Management LLC

Suvretta Capital Management LLC decreased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 53.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,182,791 shares of the company’s stock after selling 1,358,255 shares during the quarter. Suvretta Capital Management LLC owned 1.90% of Fulcrum Therapeutics worth $4,223,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of FULC. National Bank of Canada FI grew its holdings in shares of Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after acquiring an additional 4,000 shares during the last quarter. Profund Advisors LLC acquired a new position in shares of Fulcrum Therapeutics in the 2nd quarter valued at $68,000. China Universal Asset Management Co. Ltd. increased its stake in Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Fulcrum Therapeutics during the 2nd quarter worth about $82,000. Finally, Intech Investment Management LLC acquired a new stake in Fulcrum Therapeutics during the 3rd quarter worth about $62,000. Institutional investors own 89.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on FULC shares. HC Wainwright reiterated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Bank of America lowered shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Leerink Partnrs cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $3.00 in a research report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Price Performance

FULC opened at $3.95 on Friday. The stock has a fifty day moving average price of $3.43 and a 200 day moving average price of $6.22. Fulcrum Therapeutics, Inc. has a 1 year low of $2.86 and a 1 year high of $13.70.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.